Safety and efficacy of upadacitinib in patients with rheumatoid arthritis

A new randomised, double-blind, placebo-controlled phase 3 trial study published by Lancet.

Upadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in phase 2 studies in patients with moderate-to-severe rheumatoid arthritis

This study is a double-blind, placebo-controlled trial at 150 sites in 35 countries. We enrolled patients aged 18 years or older with active rheumatoid arthritis for 3 months or longer, who had received csDMARDs for at least 3 months with a stable dose for at least 4 weeks before study entry, and had an inadequate response to at least one of the following csDMARDs: methotrexate, sulfasalazine, or leflunomide

Clinical Trials

New-generation JAK inhibitors: how selective can they be?